✦HEALTH · 30% off Purgo Labs✦
Research Purposes Only

BPC-157 FDA Status & Regulatory Timeline 2026

Explore the current FDA status of BPC-157, its regulatory timeline, and what a potential reclassification could mean in 2026.

Current FDA Status: Category 2 Compound

As of October 2023, the U.S. Food and Drug Administration (FDA) has designated BPC-157 as a Category 2 compound under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. This classification significantly impacts its availability and legal standing within the United States.

Research-grade BPC-157: who sells it, at what price
every vendor ranked

BPC-157 is not approved for any use and is sold for in-vitro research only. Almost every vendor stocks it, so the ranking below rests on what each one can prove about the vial: a named lab, a batch-matched certificate, and a dated product-page price.

Where to buy BPC-157
35 partners · prices read from product pages, latest 18 Nov · ranked by rubric, then price

Lowest price at 10/10Premier Bio Labs has the lowest 10mg price of the 6 vendors on the full score, $17.10 with code HEALTH (list $19.00), read 8 Nov. Next is MyPurePeptide at $20.00. Worked out from the dated prices. It does not change the order below.

See it at Premier Bio Labs
  • 1
    1 certificate verified at the lab
    10mg vial$44.99
    −30%$31.49
    with code
    Buy
  • 2
    MyPurePeptide10/10Lowest per mg
    2 certificates verified at the lab
    10mg vial$25.00
    −20%$20.00
    with code
    Buy
  • 3
    1 certificate verified at the lab
    10mg vial$39.99
    −37%$25.19
    sale $27.99, then code
    Buy
Also stocked by partners we work with. Listed by our choice, outside the ranking above.
  • 2 certificates verified at the labprice read 24 Octfree account needed to see the store
    10mg vial$53.00
    −10%$47.70
    with code
    Buy
  • 2 certificates verified at the labprice read 12 Nov
    10mg vial$89.99
    −10%$80.99
    with code
    Buy
Every order also needs bacteriostatic water — add it to the same cart.All BPC-157 vendors, partners and not
BPC-157 10mg starts at $15.20 (read 26 Oct 2026). Get an email when a scored vendor goes lower or restocksJoins the Price Report, Mondays and Fridays: every BPC-157 move we read, plus the partner codes now. Unsubscribe in one click. See this week's issue.

Research use only. Prices are list prices read from each vendor's product page on the date shown; code prices are list × (1 − the stated discount), not cart-tested. We earn a commission on partner links; the rubric does not read partner status. How we score.

What Category 2 Means: Higher-Risk Designation

The Category 2 designation signifies that BPC-157 is considered a higher-risk substance when compounded. This means that compounding pharmacies are prohibited from preparing BPC-157 for human use. The FDA rationale behind this classification often involves concerns about safety, efficacy, and the lack of robust human clinical trial data to support its use.

The Regulatory Timeline: From Availability to Restriction

The regulatory journey of BPC-157 has seen significant shifts:

  • Pre-2023 Availability: Prior to October 2023, BPC-157 was more readily available through compounding pharmacies, often marketed for various therapeutic uses based largely on preclinical research.
  • October 2023 Category 2 Designation: The FDA officially designated BPC-157 as a Category 2 compound, severely restricting its compounding for human use.
  • Enforcement Actions: Following the Category 2 designation, the FDA has undertaken enforcement actions against entities found to be compounding or marketing BPC-157 for human consumption.
  • March 2026 NPR Report: A National Public Radio (NPR) report in March 2026 discussed the potential for restrictions on BPC-157 to be lifted. However, it is crucial to note that as of now, this remains a discussion, and the Category 2 designation is still in effect. Any reclassification would require formal FDA action and robust scientific evidence.

Regulatory Timeline Table

Date/PeriodEventImpact
Pre-October 2023Widespread availability through compounding pharmacies.BPC-157 often marketed for human therapeutic use.
October 2023FDA designates BPC-157 as Category 2 compound.Prohibition on compounding for human use by pharmacies.
Post-October 2023FDA enforcement actions.Increased scrutiny and legal action against non-compliant entities.
March 2026NPR report on potential lifting of restrictions.Discussion of possible reclassification, but no formal change yet.

WADA Prohibition: A Concern for Athletes

For athletes and those involved in competitive sports, it is critical to be aware that BPC-157 is listed as prohibited at all times by the World Anti-Doping Agency (WADA) on its 2026 Prohibited List. This means that its use is banned both in-competition and out-of-competition, and detection can lead to severe penalties.

State-Level Variation: Navigating Local Regulations

While federal regulations set a baseline, the legal landscape for substances like BPC-157 can also vary at the state level. Some states may have additional restrictions or interpretations that differ from federal guidelines. Therefore, it is essential for individuals and businesses to consult local laws and regulations regarding the possession, sale, and use of BPC-157 to ensure full compliance.

What a Potential Reclassification Would Mean

The discussion surrounding a potential reclassification of BPC-157, as highlighted by the March 2026 NPR report, suggests a future where its regulatory status could change. If BPC-157 were to be reclassified and removed from the Category 2 list, it could potentially allow compounding pharmacies to prepare it for human use once again. This would significantly impact its availability, perceived safety, and the scope of its potential applications.

However, any such reclassification would undoubtedly be contingent upon the presentation of more robust human clinical trial data, demonstrating both its safety and efficacy for specific medical conditions. Until then, BPC-157 remains an investigational compound with significant regulatory restrictions.

Frequently Asked Questions (FAQ)

For detailed answers to common questions about BPC-157's FDA status and regulatory timeline, please refer to the FAQ schema embedded in this page's metadata.

Related BPC-157 Guides